Member Info for NFTs

I wonder how the serpent got on slivering around at Eden project today in the rain. O 🐍 how they don’t like the rain.

Cannot believe I didn’t spot this earlier and explains everything about the writing style, pretending they don’t know about the science but playing it big time!!! The desperate levels people go to.

Touck has all the similarities of a person who’s name is associated to a serpent slivering their way to Eden.

I never put this as a thought before but I now wonder if they are. Makes sense.

Historically, Avacta has followed a very specific pattern: they use medical shows for "new" deep-dive data and RNS results days for "operational" updates.

However, based on their previous guidance and today's context, here is how those "two lots of data" actually break down:

1. The ASCO "Show" Data (June 2026)

You are correct—ASCO (American Society of Clinical Oncology), which takes place in early June, is where the "big" new scientific data is typically reserved.

• What goes here: This is where you would expect the formal, peer-reviewed poster or oral presentation.

• The Content: This usually features the detailed survival curves and RECIST response tables that have been kept under "embargo" until the conference. If they have specific new data on the 144-patient expansion cohorts, they would save the "splash" for ASCO to get global pharma's attention.

2. The Results Day "Operational" Update (May 19, 2026)

While the May 19 presentation won't "scoop" a major conference like ASCO, management often provides a "Top-Line" or "Directional" update to shareholders.

• The "Tease": They might say, "We have seen continued durability in the SGC cohort," or "Safety remains consistent as we've dosed more patients in the expansion phase."

• What they can discuss: They can confirm that the data cut-off for the conference has happened and whether the results met their internal expectations.

• The "New" Non-Data info: They will likely discuss the Sustained Release mechanism (the "Gen 2" tech) in more detail, as this is intellectual property progress rather than just clinical trial results.

Why it feels like "two lots"

Management has often referred to two distinct data sets they are working toward:

1. The Salivary Gland Cancer (SGC) maturity data: Showing how long the responses actually last (PFS).

2. The Triple Negative Breast Cancer (TNBC) initial data: This is the newer cohort where investors are looking for proof that AVA6k works in a much larger market than just SGC.

The likely reality for the May 19th presentation:

They will confirm that the TNBC data is "on track" for a specific upcoming show (potentially ESMO later in the year) while giving a "directional" thumbs-up on the SGC data that will be fully detailed at ASCO in June

While the headline focuses on "Preliminary Results" (financials), the conclusion that a clinical update is coming is based on the specific wording regarding the Investor Meet Company presentation scheduled for May 19, 2026.

1. Where it says it in the RNS

In the RNS, the company confirms:

"Christina Coughlin, Chief Executive Officer, and Brian Hahn, Chief Financial Officer, will deliver a live presentation via Investor Meet Company at 14:00 BST on May 19, 2026."

2. Why this implies a Clinical Update

The conclusion that this constitutes a "business and clinical update" is drawn from three specific factors:

• The Presenters: Christina Coughlin is the CEO but also a medical doctor (MD, PhD). In previous RNS notices (such as the Q1 Business Update), her role in these presentations is explicitly to bridge the gap between financial results and the clinical progression of the pre|CISION® platform. 

• The "Investor Meet Company" Format: This platform is Avacta’s primary vehicle for detailed technical and clinical briefings. Today's RNS notes that the presentation is "open to all existing and potential shareholders" and allows for a Q&A session. Historically, Avacta uses these sessions to provide "context" to the numbers, which for a clinical-stage biotech, is almost entirely driven by trial data (AVA6000, AVA6103). 

• Context from the Q1 Update: In the April 9, 2026, "Business Update," Avacta explicitly tied their financial reporting cycle to "value inflection points" throughout the year. Because they mentioned in that update that "A clinical data update on Gen One AVA6000... is expected in H1 2026," and we are now in mid-May (the end of H1), the May 19th presentation is the scheduled venue for that promised clinical commentary.

Typically, any interest that had accrued on that specific £1.2m since the last payment date is extinguished. It isn't paid in cash, and it isn't added to the share count. The bondholder effectively "forfeits" the small amount of accrued interest in exchange for the immediate benefit of getting shares at a discount (75p) while the market price is high (85p+).

The May 19th RNS isn't just a boring spreadsheet of last year's finances; it is set to be a major "value inflection point" for the company.

While the primary purpose is the Full Year 2025 Preliminary Results, Avacta has explicitly stated they will provide a business and clinical update alongside it. Here is exactly what is expected: 

1. AVA6000 (Gen One) Update

This is the "big one." The market is expecting updated data from the Phase 1a and Phase 1b cohorts. 

• Efficacy: Specifically looking for more "Objective Response" data in the Salivary Gland Cancer (SGC) cohort, which has been their lead indication. 

• Safety: Expecting more detail on the cardiac safety data. Remember, the health authorities recently removed the "lifetime maximum dose" limit for this drug—which is unheard of for doxorubicin. Investors want to see the hard data that justified that move. 

2. AVA6103 (Gen Two) Progress

Since the first patient was treated in the FOCUS-01 trial back in March, investors are looking for a status update on enrollment and perhaps some early "translational" (biological) observations. 

• The Goal: Validating that their "sustained release" mechanism works as well in humans as it did in the preclinical models they showed at the AACR conference in April.

3. Partnership "Teasers"

CEO Christina Coughlin has been vocal about "substantial interest from multiple parties" regarding their assets. 

• The Hope: Any hint that they are moving closer to a licensing deal or a major partnership. This is what usually drives the share price up sustainably.

4. Cash Runway

Following the £10m raise in March, they should confirm they are funded into early Q1 2027. This removes the immediate fear of another "emergency" fundraise. 

Why the May 19th date matters for the bond conversion:

Going back to your earlier point: HCI converting today suggests they want their shares in hand before the 19th

The article announces that AffyXell Therapeutics—which is the joint venture created by Avacta and the South Korean pharmaceutical giant Daewoong Pharmaceutical—has just signed a joint research, development, and licensing agreement with another biotech company called ProAbTech.

They are teaming up to develop "next-generation targeted protein degradation (TPD) drugs" for difficult-to-treat conditions like solid tumors and autoimmune diseases.

Here is exactly what this development means for Avacta:

1. Entering a Highly Lucrative Scientific Space (TPD)

Targeted Protein Degradation (TPD) is currently one of the hottest areas in biopharma. Instead of just blocking a disease-causing protein (like traditional drugs do), TPD acts like a molecular hitman, hijacking the cell's natural waste disposal system to completely destroy the bad protein.

• The Affimer Connection: ProAbTech likely brings the specific degradation technology, but they need a way to guide that "hitman" to the right cells. That is where Avacta’s Affimer technology comes in. AffyXell uses Affimers for precise targeting. This proves that Avacta’s Affimer platform is highly versatile and can be plugged into cutting-edge modalities like TPD.

2. Upside Without the Cash Burn

Avacta’s primary focus right now is funding and running clinical trials for its in-house oncology drugs (like AVA6000 and AVA6103).

• The Financial Benefit: Because AffyXell is a joint venture, this new R&D agreement with ProAbTech is funded and managed by the JV, not directly by Avacta. Avacta gets to maintain a significant equity stake and reap the rewards of any downstream success, milestone payments, or out-licensing deals without having to drain its own £10 million cash runway to fund the lab work.

3. Boosting the Joint Venture's Valuation

This news stacks on top of other recent momentum for AffyXell. Recently, the manufacturing giant GenScript ProBio expanded its partnership with AffyXell and committed to taking a direct equity stake in the joint venture during its next funding round.

• The Strategic Angle: By expanding its pipeline into TPD with ProAbTech, AffyXell is making itself a much more valuable, multi-asset company. If AffyXell is eventually bought out or spun off, Avacta’s piece of that pie just got inherently more valuable.

The Bottom Line

For Avacta, this is excellent "background" news. Management has made it clear that Avacta is transitioning into a pure-play, clinical-stage oncology company focused heavily on its pre|CISION drug delivery platform. However, this Korean news proves that their older, foundational Affimer platform continues to actively generate value, secure deals, and act as a hidden growth engine through strategic partnerships.

https://mobile.newsis.com/view/NISX20260512_0003625511#_PA

What do you want to know? It’s all there in black and white, if the majors don’t buy it another will and they lose.

We as holders want that after 1st AVA6103 readout for obvious reasons. It proves 2nd drug with precision platform proving its replication now on over 500 molecules.

It will become one the most powerful drugs and delivery systems on the entire market of over 300 billion PA.

We expect readouts on AVA6k this H1 with a deal to finance the company through readout on AVA6103 giving them power to negotiate a deal with strong hand along with the curveball of one the already outsourced molecules….

None of this is fact, it’s a story.

RAH is a guy who sits in a group could be called TVR5. They makeup a group of old holders who picked up millions of cheap stock back in 2020 raise along with RH Zues.

They have an ear to the city RH.

So, it’s very close to the drinking source. Used to be very direct source in the older days of AS.

It’s not a bad thing, but RAH is a younger lad so he has his irrational moods. They obviously astute but not clairvoyant. It’s easy to sound super clever when you get fed decent news!!!

Immaterial though to the actual fact, AVACTA is a huge huge incoming rise and buyout.

End of story. All fictional and names not connected

Acknowledgement you're referring to from yesterday (May 6, 2026) centers on AVA6103 (FAP-Exd) and its performance metrics compared to industry-leading Antibody-Drug Conjugates (ADCs) like Enhertu and Datroway. 

The "blank reality" is that Avacta is making a bold claim: their pre|CISION® platform is essentially beating the current gold standard of cancer drug delivery at its own game. Here is the breakdown of the data that has the market talking:

1. The "Staggering" Metrics

Avacta released comparative data showing that AVA6103 delivers the toxic payload (exatecan) with vastly superior efficiency than leading ADCs: 

• Payload Concentration (C_{max}): AVA6103 achieved a maximal tumor concentration of released payload that is one log higher (10x higher) than its competitors. 

• Speed of Penetration (T_{max}): AVA6103 hits the tumor in minutes, whereas the competing ADCs take over 24 hours to reach their peak concentration. 

• Tumor Selectivity Index (TSI): The "magic number" for safety. AVA6103's ratio of drug in the tumor versus drug in the blood is 3 times higher than Enhertu or Datroway. 

2. Why "Staggering" is the Right Word

In clinical terms, these aren't just incremental gains; they represent a fundamental shift in the therapeutic window. 

• High Efficacy: By getting 10x more drug into the tumor almost instantly, you potentially kill more cancer cells faster.

• Low Toxicity: Because the drug is staying in the tumor and not leaking into the bloodstream (high TSI), the "staggering" dose doesn't come with the "staggering" side effects usually associated with high-dose chemo. 

3. The Big Picture Reality

The acknowledgement yesterday effectively positions AVA6103 not just as "another drug," but as a superior delivery vehicle that works regardless of the ADC target. By comparing it directly to Enhertu (a multi-billion dollar drug), Avacta is signaling to big pharma that their platform might be the "Intel Inside" for the next generation of oncology. 

The Bottom Line:

While the preclinical data is "staggering," the reality for investors and patients is now focused on the FOCUS-01 Phase 1 trial. The "blank reality" is that if these 10x concentration levels translate from the lab to human patients later this year, the valuation of the pre|CISION® platform could undergo a massive re-rating

Today’s (May 6, 2026) Avacta Science Day in London was a high-energy "show and tell" of the company’s pivot from a single-drug company to a multi-asset platform powerhouse. 

The room was reportedly buzzing about the "Next Chapter of pre|CISION," specifically how their Gen-Two assets are outperforming the current darlings of the oncology world, Antibody-Drug Conjugates (ADCs).

1. The Head-to-Head: "Better than Enhertu?"

The biggest reveal was a data comparison between Avacta's AVA6103 and two blockbuster ADCs: Enhertu® and Datroway®. 

• The Science: ADCs depend on a specific "doorway" into the cell (like HER2 or TROP2). Avacta’s pre|CISION acts more like a "landmine" triggered by FAP (an enzyme in tumors). 

• The Comment: CEO Christina Coughlin noted that this mechanism allows for higher selectivity "regardless of the ADC target." * Key Stat: AVA6103 showed a 3x higher Tumor Selectivity Index and a tumor concentration "one log higher" than Enhertu. Essentially, they are getting significantly more medicine into the cancer with less "splash damage" to the rest of the body. 

2. The "One-Two Punch": Dual Payload (AVA6207)

They showcased updated data on AVA6207, which carries two different chemotherapy "warheads" at once. 

• The Breakthrough: For the first time, they showed an efficacy advantage over single-payload ADCs in models where the cancer was "FAP-low" (harder to find). 

• The Snippet: While tumors regrew under conventional cytotoxic treatment, the dual-payload system showed "prolonged deep complete responses." 

Best Quotes & Comments

The "vibe" from the speakers and the follow-up Q&A offered some great insights:

• On Innovation Speed: Christina Coughlin remarked, "We continue to build momentum and enhance our IP—at a pace that we are confident exceeds industry norms." (A clear nod to the rapid transition from AVA6000 to Gen-Two). 

• On the "Gold Standard": One of the scientific presenters reportedly described the pre|CISION platform as "de-coupling efficacy from the cell-surface receptor," which is a fancy way of saying they don't care if the cancer tries to "hide" its HER2 receptors; as long as the tumor environment is there, the drug will find it.

• The "Safety Shield": There was a lot of talk about the removal of the lifetime maximum dose for AVA6000. One attendee noted the comment that the cardiac safety profile was so "boring" (in a good way) that it has completely changed how clinicians view the drug's potential.

Summary of Future Milestones Mentioned:

• FOCUS-01 (AVA6103): Initial clinical data is firmly slated for H2 2026. 

• Finances: They confirmed they are funded beyond multiple "value inflection points" through the end of 2026. 

• Partnerships: Hinted at "active interactions" with big pharma who are watching the ADC vs. PDC (Peptide Drug Conjugate) data very closely.

It will likely get all the stamps of approval because it costs the government nothing to sign a piece of paper. The real "con" test comes when they ask for the multi-billion pound "Revenue Support" (subsidies) to actually build it. If the government truly is "broke," that is where the project could stall and remain a "paper-only" success story for the Labour Party's green credentials.

However, Labour’s gamble is that by 2030, the cost of not having storage (and paying wind farms to sit idle) will be higher than the cost of subsidising EPP's "mesh."

The real question is: If the technology fails or the hydrogen market never materializes, will the directors of these small firms walk away with their "consultancy fees" while the taxpayer is left with a pile of rusting pipes in the Irish Sea? Based on historical energy projects, that's exactly what many fear.

The argument that "it will never make any money" is exactly where the debate gets heated, because the financial model for projects like EnergyPathways (EPP) and their MESH project isn't based on a traditional free market—it's based on subsidies and avoided costs.

Here is why your "con" instinct has some factual weight, and where the "money" is actually supposed to come from.

1. The "Subsidy Trap"

You are largely correct that on its own, green hydrogen is currently a financial loser.

• The Problem: It costs significantly more to make than natural gas. If EPP had to sell it on the open market today, they’d go bust.

• The Solution (The "Con" part): The government is creating "Revenue Support Models." This means if the market price of hydrogen is low, the government (taxpayer) pays the company the difference to ensure they make a profit.

• The Result: It "makes money" for the company and its investors, but only because it’s being propped up by public funds or added to consumer energy bills.

2. Is EPP a Solid Business?

Looking at the company itself, there are red flags that fuel the "con" narrative:

• Penny Stock Status: EPP is a small-cap company (listed on the AIM market). These are notoriously speculative. Their stock has traded in the 5p–10p range recently. 

• Raising Cash: They recently had to raise about £1.24 million just to keep the lights on and finish "pre-development" work. Critics see this as a company that exists primarily to suck up grants and investor cash before a shovel even hits the ground. 

• The "National Significance" Shield: By getting the government to label MESH a "Project of National Significance," they gain a fast-track through planning laws, which makes the company look more valuable to investors than it might actually be based on its balance sheet. 

3. Avoiding the "Clean-Up" Bill

One of the most cynical (but mathematically sound) takes is that this is a decommissioning dodge.

• The Cost: Closing down old North Sea assets costs billions.

• The Loophole: If a company can convince the government that an old platform is part of a "Green Energy Pathway," they don't have to tear it down yet. They can keep it on the books as an "asset" and potentially get the taxpayer to fund its "repurposing" instead of the company paying to scrap it.

4. The "Wasted Wind" Argument (The Pro-Argument)

The only way this project makes money legitimately is by solving the "Curtailment" problem.

• Right now, the UK pays wind farms hundreds of millions of pounds every year to turn off because the grid can't handle the power. 

• EPP argues that their "mesh" will take that "wasted" electricity, turn it into hydrogen, and store it. In their view, "making money" comes from capturing value that is currently being thrown away.

The Verdict

If you define a "con" as "using political slogans to get taxpayer money for a commercially unproven technology," then your assessment fits the bill.

These are exceptional drill results. In the world of copper mining, seeing grades above 1% or 2% is generally considered good. Seeing multiple intercepts above 5%, 8%, or even 9%—especially at such shallow depths—is rare and highly "high-grade."

Here is a brief breakdown of why these results are significant:

1. Exceptional "High-Grade" Intercepts

The copper percentages (TCu%) in this announcement are far above industry averages for open-pit mining.

• Standouts: MNKDD010 showed 16.0m @ 8.01% and MNKDD015 showed 7.5m @ 9.17%.

• Context: Many massive global copper mines operate on grades of 0.5\% to 1.0\%. These results are roughly 5 to 10 times higher than that.

2. Shallow Depth (Low Cost)

The mineralisation starts very close to the surface (e.g., from 18m, 22m, or even 0m in trenches).

• Why it matters: Shallow ore is much cheaper to mine because you don't have to dig a massive hole (strip ratio) to get to the "good stuff." This usually leads to higher profit margins.

3. Expansion Potential

The drilling didn't just confirm what they already knew; it found new mineralisation.

• The zone has been extended by 250 metres to the east.

• It remains "open," meaning they haven't found the end of the copper yet, and Phase 2 drilling is already hunting for more.

4. Metallurgical "Fit"

The announcement highlights "copper oxide" mineralisation.

• Oxide ore is generally easier and cheaper to process using "leaching" methods compared to sulfide ores.

• Crucially, these results fit perfectly with Jubilee’s existing Sable Refinery, meaning they can turn this rock into finished copper cathode quickly without building a new plant.

Any grades above 1.84% and that’s rocket ships.

Also

Anything that mentions remains open at depth or indicates continuous mineralization.

Then the mine is gigantic resources.

The Company furthermore expects to release the phase 1 drill results of its Molefe Mine operations on Tuesday 24 March 2026.

This tells you they are very happy with the drill results tomorrow.

Pure play copper miner massively undervalued compared to others.

More than doubled its copper production last year.

A great place to be buying.

End

Monday 🔴

Have added on this drop to my position. Top management creating a mid tier minor is not to be sneezed at. They are quality. This is hugely wanted assets that no doubt the Chinese will be all over trying to secure.

Well I have added significantly to my position here.

It’s fairly rock solid undervalued. Current war only adds to its undervalued market and I potentially see this getting bought out by a major when they open up the Vietnam gas. Get the Vietnam partnership done which is obviously who it will be and this races off.